EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem‐like properties and drug resistance were associated with EMT. Furthermore,...
Uložené v:
| Vydané v: | Cancer communications (London, England) Ročník 41; číslo 3; s. 199 - 217 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
John Wiley & Sons, Inc
01.03.2021
John Wiley and Sons Inc Wiley |
| Predmet: | |
| ISSN: | 2523-3548, 2523-3548 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem‐like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT‐associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then, we reviewed the interaction between EMT‐associated miRNAs and the drug‐resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors.
In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then we reviewed the interaction between drug resistance and EMT‐associated miRNAs with elaborated signal pathways, especially the opposite roles in various cancer types. We finally arrived at a conclusion concerning the relationship between EMT, stemness and drug resistance and discussed the potential application of miRNA therapy for malignant tumors. |
|---|---|
| AbstractList | Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem‐like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT‐associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then, we reviewed the interaction between EMT‐associated miRNAs and the drug‐resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors.
In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then we reviewed the interaction between drug resistance and EMT‐associated miRNAs with elaborated signal pathways, especially the opposite roles in various cancer types. We finally arrived at a conclusion concerning the relationship between EMT, stemness and drug resistance and discussed the potential application of miRNA therapy for malignant tumors. Epithelial-to-mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem-like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT-associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT-associated miRNAs play in the stem-like nature of malignant cells. Then, we reviewed the interaction between EMT-associated miRNAs and the drug-resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors. Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem‐like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT‐associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then, we reviewed the interaction between EMT‐associated miRNAs and the drug‐resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors. In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then we reviewed the interaction between drug resistance and EMT‐associated miRNAs with elaborated signal pathways, especially the opposite roles in various cancer types. We finally arrived at a conclusion concerning the relationship between EMT, stemness and drug resistance and discussed the potential application of miRNA therapy for malignant tumors. Abstract Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem‐like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT‐associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT‐associated miRNAs play in the stem‐like nature of malignant cells. Then, we reviewed the interaction between EMT‐associated miRNAs and the drug‐resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors. Epithelial-to-mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem-like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT-associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT-associated miRNAs play in the stem-like nature of malignant cells. Then, we reviewed the interaction between EMT-associated miRNAs and the drug-resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors.Epithelial-to-mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou studies have indicated that both cancer stem-like properties and drug resistance were associated with EMT. Furthermore, microRNAs (miRNAs) play a pivotal role in the regulation of EMT phenotype, as a result, some miRNAs impact cancer stemness and drug resistance. Therefore, understanding the relationship between EMT-associated miRNAs and cancer stemness/drug resistance is beneficial to both basic research and clinical treatment. In this review, we preliminarily looked into the various roles that the EMT-associated miRNAs play in the stem-like nature of malignant cells. Then, we reviewed the interaction between EMT-associated miRNAs and the drug-resistant complex signaling pathways of multiple cancers including lung cancer, gastric cancer, gynecologic cancer, breast cancer, liver cancer, colorectal cancer, pancreatic cancer, esophageal cancer, and nasopharyngeal cancer. We finally discussed the relationship between EMT, cancer stemness, and drug resistance, as well as looked forward to the potential applications of miRNA therapy for malignant tumors. |
| Author | Zhou, Fangyuan Pan, Guangtao Shang, Luorui Yang, Shenglan Liu, Yuhan |
| AuthorAffiliation | 1 Department of Traditional Chinese Medicine Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 P. R. China |
| AuthorAffiliation_xml | – name: 1 Department of Traditional Chinese Medicine Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 P. R. China |
| Author_xml | – sequence: 1 givenname: Guangtao surname: Pan fullname: Pan, Guangtao organization: Huazhong University of Science and Technology – sequence: 2 givenname: Yuhan surname: Liu fullname: Liu, Yuhan organization: Huazhong University of Science and Technology – sequence: 3 givenname: Luorui surname: Shang fullname: Shang, Luorui organization: Huazhong University of Science and Technology – sequence: 4 givenname: Fangyuan surname: Zhou fullname: Zhou, Fangyuan organization: Huazhong University of Science and Technology – sequence: 5 givenname: Shenglan orcidid: 0000-0002-4807-950X surname: Yang fullname: Yang, Shenglan email: yangshenglan005@163.com organization: Huazhong University of Science and Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33506604$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1qFDEUgINUbK298QFkwBsRtuY_mRthWVotVEXZ-5BkzmyzzCQ1mVF65yP0GX0SZzu1tEW8Ssj5zsc5Oec52ospAkIvCT4mGNN33np6TChh-gk6oIKyBRNc792776OjUrYYY1Lrmgv2DO0zJrCUmB-gryef1r9_XdtSkg92gKbqg8_p2-dlqWxsquECQq5y6qBUIVbeRg-5KgP0EcqMNHncVBlKKMMu-gI9bW1X4Oj2PETr05P16uPi_MuHs9XyfOGFJnoBBLQitHWNkOCZw0LxmjHpFLTOctxiYTXWRDrhoCYMFGXMcyobxR1gdojOZm2T7NZc5tDbfGWSDebmIeWNsXkIvgNDwLd1A1ZqC9wRqC32ilGgrbACOzK53s-uy9H10HiIQ7bdA-nDSAwXZpN-GFVLrTWfBG9uBTl9H6EMpg_FQ9fZCGkshnJNpaQ1phP6-hG6TWOO008ZqjBVnDBWT9Sr-xXdlfJ3cBPwdgamYZWSob1DCDa7xTC7xTA3izHB-BHsw2CHkHbdhO7fKWRO-Rk6uPqP3KyWKzrn_AEauMnP |
| CitedBy_id | crossref_primary_10_3389_fmicb_2023_1147778 crossref_primary_10_1016_j_bbadis_2024_167210 crossref_primary_10_1016_j_ebiom_2024_105309 crossref_primary_10_1007_s10637_025_01555_2 crossref_primary_10_3389_fonc_2025_1576895 crossref_primary_10_1002_cam4_70296 crossref_primary_10_3389_fbioe_2024_1457884 crossref_primary_10_1016_j_gene_2024_148293 crossref_primary_10_1002_jbt_70244 crossref_primary_10_1155_2022_1289445 crossref_primary_10_1002_jbt_70499 crossref_primary_10_1002_jcp_31344 crossref_primary_10_1155_2022_6530454 crossref_primary_10_3892_or_2023_8647 crossref_primary_10_1016_j_humimm_2024_111221 crossref_primary_10_1016_j_biopha_2023_115349 crossref_primary_10_3390_bioengineering10080892 crossref_primary_10_1111_cas_15687 crossref_primary_10_3390_ijms242316872 crossref_primary_10_1515_biol_2022_1007 crossref_primary_10_3389_fnut_2022_1001334 crossref_primary_10_1007_s40203_024_00213_4 crossref_primary_10_1016_j_ecoenv_2022_114270 crossref_primary_10_1016_j_tranon_2024_102166 crossref_primary_10_3389_fonc_2023_1236679 crossref_primary_10_1093_hmg_ddae001 crossref_primary_10_1038_s41419_024_06673_y crossref_primary_10_1016_j_biopha_2023_114487 crossref_primary_10_3390_ijms24108502 crossref_primary_10_1186_s12967_023_04030_9 crossref_primary_10_1186_s12935_025_03713_1 crossref_primary_10_3389_fonc_2023_1121416 crossref_primary_10_1080_07853890_2024_2442067 crossref_primary_10_1002_fsn3_4744 crossref_primary_10_1080_07853890_2024_2424513 crossref_primary_10_1016_j_apsb_2025_03_048 crossref_primary_10_1016_j_prp_2022_153763 crossref_primary_10_3892_mmr_2021_12466 crossref_primary_10_61958_NCAK2947 crossref_primary_10_1007_s12013_024_01290_0 crossref_primary_10_1007_s12015_024_10691_w crossref_primary_10_3390_ijms242417523 crossref_primary_10_3389_fgene_2022_921837 crossref_primary_10_3390_ijms24087126 crossref_primary_10_34133_bmef_0144 crossref_primary_10_3390_genes14111994 crossref_primary_10_1007_s10555_023_10162_7 crossref_primary_10_1007_s13273_023_00407_5 crossref_primary_10_3390_molecules27113513 crossref_primary_10_1016_j_taap_2024_116807 crossref_primary_10_3390_ijms25105102 crossref_primary_10_1002_tox_24292 crossref_primary_10_1016_j_jbc_2025_108234 crossref_primary_10_1016_j_prp_2022_154227 crossref_primary_10_1016_j_gmg_2025_100067 crossref_primary_10_1016_j_biopha_2022_113774 crossref_primary_10_3390_pharmaceutics17040479 crossref_primary_10_3390_cancers15041230 crossref_primary_10_1016_j_heliyon_2024_e31778 crossref_primary_10_1016_j_semcancer_2023_04_005 crossref_primary_10_1038_s41698_025_01030_4 crossref_primary_10_2174_0109298673285341231226111553 crossref_primary_10_3390_cancers13143409 crossref_primary_10_3389_fphar_2023_1217001 crossref_primary_10_1002_cam4_70412 crossref_primary_10_1017_erm_2023_16 crossref_primary_10_1016_j_yexcr_2025_114661 crossref_primary_10_31083_j_fbl2810271 crossref_primary_10_3389_fonc_2022_965628 crossref_primary_10_1007_s12033_023_00782_3 crossref_primary_10_1080_14756366_2024_2318645 crossref_primary_10_1016_j_biopha_2024_116412 crossref_primary_10_1016_j_tranon_2023_101766 crossref_primary_10_1016_j_heliyon_2024_e26604 crossref_primary_10_3389_fgene_2021_678194 crossref_primary_10_1038_s41392_023_01341_7 crossref_primary_10_1007_s13577_021_00578_0 crossref_primary_10_1007_s10238_025_01775_z crossref_primary_10_1016_j_apsb_2024_07_013 crossref_primary_10_3390_vetsci10010019 crossref_primary_10_1002_jcb_30473 crossref_primary_10_3390_cancers16091729 crossref_primary_10_1007_s12094_022_02984_8 crossref_primary_10_1016_j_ijbiomac_2025_147664 crossref_primary_10_1016_j_envres_2023_117203 crossref_primary_10_1016_j_tranon_2024_102125 crossref_primary_10_1016_j_drup_2024_101152 crossref_primary_10_1016_j_tranon_2024_102244 crossref_primary_10_1016_j_phymed_2024_155431 crossref_primary_10_3389_fendo_2025_1664604 crossref_primary_10_1038_s41598_022_10662_6 crossref_primary_10_1080_10667857_2023_2288780 crossref_primary_10_3390_genes14112073 crossref_primary_10_1002_ctd2_70011 crossref_primary_10_1002_mog2_70039 crossref_primary_10_3390_ijms24108824 crossref_primary_10_1016_j_celrep_2025_115592 crossref_primary_10_1186_s12957_025_03996_8 crossref_primary_10_1080_20002297_2025_2482924 crossref_primary_10_1016_j_ygeno_2023_110718 crossref_primary_10_3389_fcell_2024_1499111 crossref_primary_10_3390_cancers15123152 crossref_primary_10_1007_s10585_022_10172_9 crossref_primary_10_1093_jleuko_qiaf066 crossref_primary_10_1186_s12890_022_02267_6 crossref_primary_10_1016_j_yexcr_2024_114267 crossref_primary_10_1038_s41388_025_03460_7 crossref_primary_10_1016_j_molstruc_2025_142290 crossref_primary_10_1111_vox_13685 crossref_primary_10_1007_s11033_023_08801_x crossref_primary_10_1093_toxres_tfae110 crossref_primary_10_1186_s12964_023_01225_x crossref_primary_10_1007_s12672_024_01139_1 crossref_primary_10_3389_fonc_2024_1407434 crossref_primary_10_3389_fcell_2025_1583255 crossref_primary_10_1166_jbn_2025_3941 crossref_primary_10_1159_000515548 crossref_primary_10_1016_j_gene_2022_147129 crossref_primary_10_1080_14737140_2023_2219451 crossref_primary_10_3389_fmolb_2023_1297611 crossref_primary_10_1186_s12943_025_02391_x crossref_primary_10_3389_fonc_2022_1054846 crossref_primary_10_1002_cbf_3949 crossref_primary_10_3233_CBM_210213 crossref_primary_10_3892_or_2023_8598 crossref_primary_10_1007_s00210_024_03189_2 crossref_primary_10_1186_s13046_024_03021_y crossref_primary_10_1155_2022_3969389 crossref_primary_10_1002_mco2_93 crossref_primary_10_3390_cancers16010180 crossref_primary_10_1186_s13104_023_06343_w crossref_primary_10_1080_21655979_2022_2088497 crossref_primary_10_3389_fgene_2022_833362 crossref_primary_10_1007_s12032_024_02528_w crossref_primary_10_3389_fcell_2024_1390704 crossref_primary_10_3389_fdmed_2021_799716 crossref_primary_10_1016_j_biopha_2025_118572 crossref_primary_10_1016_j_heliyon_2023_e20164 crossref_primary_10_3390_pharmaceutics15082061 crossref_primary_10_3892_ijo_2025_5774 crossref_primary_10_1073_pnas_2207898120 crossref_primary_10_1016_j_canlet_2023_216261 crossref_primary_10_1016_j_adcanc_2022_100039 crossref_primary_10_1007_s12032_023_01980_4 crossref_primary_10_1016_j_ijbiomac_2024_133171 crossref_primary_10_1002_jgm_3531 crossref_primary_10_31083_CEOG39988 crossref_primary_10_1080_0886022X_2024_2316259 crossref_primary_10_1177_03946320231210737 crossref_primary_10_3390_biom12020187 crossref_primary_10_3390_ijms22147526 crossref_primary_10_1186_s12964_023_01368_x crossref_primary_10_3390_antiox14070879 crossref_primary_10_1007_s10528_022_10278_5 crossref_primary_10_1016_j_ejphar_2024_176592 crossref_primary_10_1016_j_isci_2024_111487 crossref_primary_10_1016_j_biopha_2024_116660 crossref_primary_10_3389_fonc_2023_1189635 crossref_primary_10_1002_mc_23914 crossref_primary_10_3390_ijms24076193 crossref_primary_10_3892_ol_2025_15118 crossref_primary_10_3390_medicina58040467 crossref_primary_10_3390_cancers14081866 crossref_primary_10_1186_s13071_025_06689_z crossref_primary_10_1155_2022_9302403 crossref_primary_10_1016_j_cyto_2022_155830 crossref_primary_10_1002_tox_24082 crossref_primary_10_1016_j_biopha_2024_116310 crossref_primary_10_3390_pharmaceutics15030810 crossref_primary_10_3390_biomedicines9050579 crossref_primary_10_1186_s12967_023_04120_8 crossref_primary_10_1002_ctm2_992 crossref_primary_10_1186_s12967_023_04238_9 crossref_primary_10_1016_j_prp_2024_155619 crossref_primary_10_1007_s10528_025_11057_8 crossref_primary_10_1155_2022_8799319 crossref_primary_10_1007_s12010_022_04253_4 crossref_primary_10_1038_s41401_025_01650_3 crossref_primary_10_1038_s41392_022_00889_0 crossref_primary_10_1093_bjd_ljad335 crossref_primary_10_1016_j_arr_2024_102576 crossref_primary_10_3389_fphar_2022_934534 crossref_primary_10_1016_j_jconrel_2023_09_044 crossref_primary_10_1016_j_jbc_2024_107826 crossref_primary_10_1007_s12672_024_01330_4 crossref_primary_10_1016_j_bbcan_2022_188772 crossref_primary_10_3390_ph16030374 crossref_primary_10_1186_s13046_022_02368_4 crossref_primary_10_1002_adtp_202500238 crossref_primary_10_1016_j_prp_2024_155328 crossref_primary_10_1002_cac2_12194 crossref_primary_10_1186_s12967_023_04401_2 crossref_primary_10_3389_fcell_2021_791892 crossref_primary_10_3390_biomedicines10092148 crossref_primary_10_3390_ijms26072830 crossref_primary_10_3892_or_2023_8687 crossref_primary_10_3389_fonc_2024_1374743 crossref_primary_10_1016_j_biopha_2022_112972 crossref_primary_10_1016_j_bbcan_2023_189052 crossref_primary_10_1002_cac2_12518 crossref_primary_10_1007_s12032_024_02328_2 crossref_primary_10_3389_fonc_2023_1093063 crossref_primary_10_1016_j_bbrc_2025_151519 crossref_primary_10_1155_humu_6705599 crossref_primary_10_3390_cells13110948 crossref_primary_10_1016_j_clinbiochem_2023_110657 crossref_primary_10_1111_hel_12941 crossref_primary_10_3389_fonc_2021_795633 crossref_primary_10_1016_j_snb_2023_135180 crossref_primary_10_3389_fphar_2023_1153991 crossref_primary_10_1186_s13008_023_00083_w crossref_primary_10_3389_fphar_2024_1437022 crossref_primary_10_1007_s00432_023_05030_4 crossref_primary_10_1186_s13148_024_01663_5 crossref_primary_10_3390_life13061361 crossref_primary_10_3389_fonc_2022_875188 crossref_primary_10_1038_s12276_022_00786_0 crossref_primary_10_1097_CCO_0000000000000912 crossref_primary_10_32708_uutfd_917784 crossref_primary_10_1038_s41392_023_01383_x crossref_primary_10_1007_s10495_024_01967_0 |
| Cites_doi | 10.1074/jbc.M110.152306 10.1016/j.ymthe.2019.08.015 10.1159/000482025 10.1016/j.lungcan.2008.05.017 10.1186/s40880-019-0393-5 10.3892/ijo.2016.3331 10.1126/science.aau6977 10.1016/j.molonc.2015.04.015 10.1038/cddis.2011.61 10.1038/onc.2013.322 10.1186/s13045-017-0547-3 10.1073/pnas.1812876116 10.1159/000460618 10.1186/1476-4598-13-245 10.1158/0008-5472.CAN-14-0110 10.1159/000490871 10.1016/j.omtn.2019.07.025 10.3892/ijmm.2017.2992 10.1007/s00109-014-1160-3 10.7150/thno.20725 10.1002/jcp.27679 10.1002/tox.22437 10.3892/ol.2018.8877 10.1080/15384101.2017.1367071 10.1186/s13046-016-0296-0 10.1016/j.biopha.2018.03.028 10.3892/ijo.2019.4676 10.1038/nature03315 10.1016/j.scr.2013.09.011 10.1038/nrm2868 10.1016/j.ymthe.2017.12.023 10.1002/cam4.1294 10.3892/ijo.2018.4601 10.15252/emmm.201404396 10.1016/j.ymthe.2018.01.001 10.1002/jcp.27740 10.1091/mbc.E11-02-0103 10.1073/pnas.1217519109 10.1038/s41419-018-0592-z 10.1111/cas.13104 10.1038/srep40847 10.1038/s41598-019-48081-9 10.1186/s12885-016-2916-7 10.1038/onc.2016.332 10.1159/000503225 10.1038/nature15748 10.1371/journal.pone.0093917 10.1186/s13045-019-0841-3 10.1016/j.ccr.2012.12.021 10.1371/journal.pone.0172115 10.1158/0008-5472.Can-05-1058 10.1093/abbs/gmt113 10.1172/JCI73048 10.1186/s12859-017-1467-5 10.1002/ijc.28782 10.5483/BMBRep.2018.51.9.104 10.1016/s1499-3872(14)60029-1 10.1038/embor.2008.74 10.1016/j.ymthe.2018.01.023 10.1016/j.canlet.2017.05.007 10.1002/hed.21540 10.1016/j.biopha.2018.07.059 10.3389/fonc.2019.00894 10.1038/s41598-018-30978-6 10.1038/bjc.2017.102 10.1177/1535370215584935 10.1096/fj.201801013R 10.1016/j.ymthe.2019.02.002 10.1038/aps.2017.178 10.1002/jcb.26145 10.1007/s00432-012-1154-x 10.1038/s41598-017-04097-7 10.1016/j.gene.2019.05.058 10.1172/jci65871 10.1007/s00018-011-0735-1 10.15252/embr.201540678 10.1242/jcs.123414 10.1371/journal.pone.0030771 10.1158/1535-7163.MCT-17-0925 10.1016/j.gene.2018.02.003 10.1186/s12943-016-0502-x 10.3390/cells8101118 10.1111/cas.13588 10.1186/s13045-019-0840-4 10.1186/s12943-019-0988-0 10.4161/cc.10.12.15620 10.1097/SLA.0000000000000223 10.7150/ijbs.38000 10.1016/j.ygyno.2008.08.017 10.1016/j.omtn.2018.09.026 10.1038/cddis.2017.530 10.1172/JCI73351 10.1093/intimm/dxq030 10.1186/s13045-019-0707-8 10.1038/ncomms3980 10.1074/jbc.A110.101055 10.1186/1471-2407-14-651 10.1016/j.ejca.2014.09.008 10.1038/s41417-017-0005-y 10.1038/srep27157 10.3324/haematol.2012.071753 10.1002/hep.27887 10.26355/eurrev_201809_15809 10.1038/s41388-018-0276-2 10.1038/s41598-018-27021-z 10.1074/jbc.M117.775080 10.1097/sla.0000000000001928 10.3390/ijms18040890 10.1038/cdd.2013.167 10.1016/j.biopha.2018.06.114 10.1186/s13045-018-0605-5 10.1146/annurev-pathol-020117-043854 10.3390/cancers11101549 10.1002/1878-0261.12096 10.1016/j.semcancer.2017.02.004 10.1007/s13238-014-0088-2 10.1158/0008-5472.Can-14-0110 10.1016/s0092-8674(04)00045-5 10.1158/1078-0432.CCR-16-2813 10.1158/1078-0432.Ccr-05-1492 10.1016/j.ccr.2011.12.029 10.1038/s41586-018-0040-3 10.1016/j.ebiom.2018.08.001 10.1016/j.semcancer.2018.08.003 10.1038/onc.2017.4 10.1186/s13045-020-00849-7 10.1159/000457879 10.1186/s13045-020-0845-z 10.1016/j.canlet.2012.04.016 10.7150/thno.37717 10.1038/cddis.2017.544 10.1186/s13046-019-1195-y 10.15252/embj.201489574 10.1158/1535-7163.Mct-13-0448 10.1186/s13046-016-0415-y 10.1038/onc.2011.260 10.3892/ijo.2018.4409 10.1038/s41598-017-04191-w 10.1016/j.gene.2019.03.043 10.1016/j.ctrv.2013.09.008 10.18632/oncotarget.4629 10.1038/nrc3130 10.1002/gcc.20902 10.1371/journal.pone.0059104 10.1016/j.bbrc.2014.03.135 10.1038/aps.2017.164 10.1186/s13046-018-0677-7 10.1158/1535-7163.MCT-14-0207 10.1038/s41419-018-0732-5 10.1038/onc.2016.201 10.1016/j.phrs.2019.104390 10.1128/mcb.00941-08 10.1186/s13046-017-0520-6 10.1186/s12943-019-0981-7 10.1002/cam4.690 10.1002/iub.1720 10.1016/j.ceb.2016.06.002 10.1038/s41598-018-19339-5 10.1186/s13046-019-1370-1 10.1038/onc.2016.414 10.1038/srep42226 10.1016/j.biocel.2018.06.007 10.1002/ijc.33386 10.18632/oncotarget.25692 10.1002/jcb.29554 10.1186/s13045-019-0708-7 10.7314/apjcp.2013.14.3.1715 10.1038/nature09267 10.1016/j.semcancer.2018.08.008 10.1111/jcmm.14090 10.1038/cgt.2014.73 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center – notice: 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/cac2.12138 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | PAN et al |
| EISSN | 2523-3548 |
| EndPage | 217 |
| ExternalDocumentID | oai_doaj_org_article_1ecf9dea68ae4b1e9a0c732e2f5a50b1 PMC7968884 33506604 10_1002_cac2_12138 CAC212138 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | 0R~ 1OC 24P 7RV 7X7 88E 8FI 8FJ ABUWG ACCMX ACRMQ ACXQS ADKYN ADPDF ADUKV ADZMN ADZOD AFKRA AHSBF ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AVUZU AZQEC BENPR BMC C24 C6C CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW ITC K9- M0R M1P M~E NAPCQ OK1 OVD OVEED PIMPY PSQYO ROL RPM RSV SOJ TEORI UKHRP WIN AAYXX AENVI AFFHD CITATION PHGZM PHGZT PJZUB PPXIY NPM 3V. 7XB 8FK DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c5818-e1e8712fbd56ec3b05749336b7efba40f05a80816b5be913e7233c426d74be03 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 265 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000614106100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2523-3548 |
| IngestDate | Tue Oct 14 15:13:36 EDT 2025 Tue Nov 04 01:59:19 EST 2025 Wed Oct 01 14:54:50 EDT 2025 Sat Nov 29 14:48:38 EST 2025 Thu Apr 03 06:52:25 EDT 2025 Tue Nov 18 22:29:05 EST 2025 Sat Nov 29 03:50:10 EST 2025 Wed Jan 22 16:29:31 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | microRNA cancer drug resistance cancer stem cell cancer stemness epithelial-to-mesenchymal transition |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5818-e1e8712fbd56ec3b05749336b7efba40f05a80816b5be913e7233c426d74be03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-4807-950X |
| OpenAccessLink | https://www.proquest.com/docview/2702741339?pq-origsite=%requestingapplication% |
| PMID | 33506604 |
| PQID | 2702741339 |
| PQPubID | 2040150 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1ecf9dea68ae4b1e9a0c732e2f5a50b1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7968884 proquest_miscellaneous_2482662902 proquest_journals_2702741339 pubmed_primary_33506604 crossref_primary_10_1002_cac2_12138 crossref_citationtrail_10_1002_cac2_12138 wiley_primary_10_1002_cac2_12138_CAC212138 |
| PublicationCentury | 2000 |
| PublicationDate | March 2021 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: March 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Cancer communications (London, England) |
| PublicationTitleAlternate | Cancer Commun (Lond) |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2010; 11 2014; 259 2013; 4 2015; 70 2013; 68 2019; 11 2010; 466 2019; 12 2013; 126 2019; 15 2013; 123 2019; 18 2005; 65 2016; 264 2020; 13 2013; 8 2016; 35 2018; 47 2014; 21 2014; 135 2018; 7 2010; 22 2018; 9 2018; 8 2018; 39 2019; 23 2008; 28 2016; 43 2019; 27 2019; 710 2014; 14 2014; 13 2011; 68 2008; 111 2012; 138 2016; 48 2014; 12 2012; 21 2018; 37 2014; 124 2018; 35 2019; 8 2015; 240 2019; 9 2009; 63 2011; 2 2018; 106 2018; 102 2018; 101 2019; 39 2019; 38 2010; 285 2015; 527 2018; 109 2016; 17 2014; 40 2018; 22 2016; 16 2016; 15 2018; 26 2012; 31 2012; 109 2018; 25 2016; 5 2016; 6 2018; 17 2015; 62 2013; 338 2020; 28 2016; 20 2018; 11 2016; 291 2018; 16 2005; 11 2018; 13 2017; 40 2015; 34 2017; 7 2017; 8 2017; 41 2013; 23 2019; 54 2017; 44 2017; 43 2008; 9 2011; 11 2011; 10 2020; 367 2017; 116 2017; 118 2014; 447 2014; 5 2013; 14 2017; 36 2013; 98 2018; 652 2017; 32 2018; 70 2019; 116 2019; 234 2011; 22 2014; 9 2014; 50 2017; 402 2015; 6 2014; 92 2013; 45 2005; 433 2017; 23 2017; 292 2011; 33 2019; 147 2019; 700 2015; 9 2015; 7 2017; 108 2004; 116 2018; 556 2013; 32 2017; 16 2020 2017; 11 2015; 22 2017; 12 2011; 50 2019 2018 2017; 18 2018; 51 2014; 74 2012; 7 2018; 53 e_1_2_9_75_1 e_1_2_9_98_1 e_1_2_9_52_1 e_1_2_9_79_1 e_1_2_9_94_1 e_1_2_9_10_1 e_1_2_9_56_1 e_1_2_9_33_1 e_1_2_9_90_1 e_1_2_9_71_1 e_1_2_9_103_1 e_1_2_9_149_1 e_1_2_9_107_1 Luan QX (e_1_2_9_110_1) 2016; 20 e_1_2_9_122_1 e_1_2_9_145_1 e_1_2_9_168_1 e_1_2_9_14_1 e_1_2_9_141_1 e_1_2_9_37_1 e_1_2_9_164_1 e_1_2_9_18_1 e_1_2_9_160_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_87_1 Wei T (e_1_2_9_80_1) 2017; 7 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_68_1 e_1_2_9_83_1 e_1_2_9_6_1 e_1_2_9_119_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_138_1 e_1_2_9_111_1 e_1_2_9_134_1 e_1_2_9_115_1 e_1_2_9_157_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_130_1 e_1_2_9_176_1 e_1_2_9_153_1 e_1_2_9_172_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_99_1 e_1_2_9_72_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_95_1 e_1_2_9_76_1 e_1_2_9_91_1 e_1_2_9_102_1 e_1_2_9_148_1 e_1_2_9_129_1 e_1_2_9_144_1 e_1_2_9_167_1 e_1_2_9_106_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_140_1 e_1_2_9_163_1 e_1_2_9_121_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_88_1 e_1_2_9_61_1 e_1_2_9_46_1 e_1_2_9_84_1 e_1_2_9_23_1 e_1_2_9_65_1 Ma J (e_1_2_9_125_1) 2016; 6 e_1_2_9_5_1 e_1_2_9_114_1 e_1_2_9_137_1 e_1_2_9_118_1 e_1_2_9_133_1 e_1_2_9_156_1 e_1_2_9_9_1 e_1_2_9_152_1 e_1_2_9_27_1 e_1_2_9_69_1 e_1_2_9_171_1 e_1_2_9_31_1 Gao XJ (e_1_2_9_126_1) 2015; 70 e_1_2_9_50_1 e_1_2_9_73_1 e_1_2_9_35_1 e_1_2_9_77_1 e_1_2_9_96_1 e_1_2_9_12_1 e_1_2_9_54_1 e_1_2_9_92_1 e_1_2_9_109_1 e_1_2_9_101_1 e_1_2_9_128_1 e_1_2_9_166_1 e_1_2_9_105_1 e_1_2_9_124_1 e_1_2_9_147_1 e_1_2_9_39_1 e_1_2_9_162_1 e_1_2_9_120_1 e_1_2_9_16_1 e_1_2_9_58_1 e_1_2_9_143_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_89_1 Zhan M (e_1_2_9_175_1) 2013; 68 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_85_1 e_1_2_9_8_1 e_1_2_9_81_1 e_1_2_9_4_1 e_1_2_9_113_1 e_1_2_9_159_1 e_1_2_9_117_1 e_1_2_9_155_1 e_1_2_9_136_1 e_1_2_9_151_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_132_1 e_1_2_9_174_1 e_1_2_9_170_1 e_1_2_9_74_1 e_1_2_9_51_1 e_1_2_9_78_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_97_1 e_1_2_9_93_1 e_1_2_9_108_1 e_1_2_9_70_1 e_1_2_9_127_1 e_1_2_9_100_1 e_1_2_9_123_1 e_1_2_9_169_1 e_1_2_9_104_1 e_1_2_9_146_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_142_1 e_1_2_9_165_1 e_1_2_9_161_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_21_1 e_1_2_9_67_1 e_1_2_9_44_1 e_1_2_9_86_1 e_1_2_9_7_1 e_1_2_9_82_1 e_1_2_9_3_1 e_1_2_9_112_1 e_1_2_9_139_1 e_1_2_9_116_1 e_1_2_9_135_1 e_1_2_9_158_1 e_1_2_9_177_1 e_1_2_9_25_1 e_1_2_9_131_1 e_1_2_9_154_1 e_1_2_9_173_1 e_1_2_9_48_1 e_1_2_9_29_1 e_1_2_9_150_1 |
| References_xml | – volume: 53 start-page: 31 year: 2018 end-page: 41 article-title: Replication stress response in cancer stem cells as a target for chemotherapy publication-title: Semin Cancer Biol – volume: 7 year: 2017 article-title: Targeting the miR‐200c/LIN28B axis in acquired EGFR‐TKI resistance non‐small cell lung cancer cells harboring EMT features publication-title: Sci Rep – volume: 68 start-page: 955 issue: 12 year: 2013 end-page: 61 article-title: Let‐7c sensitizes acquired cisplatin‐resistant A549 cells by targeting ABCC2 and Bcl‐XL publication-title: Pharmazie – start-page: 1 year: 2019 end-page: 13 article-title: MicroRNA‐296‐5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2‐Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer publication-title: Digestion – volume: 7 year: 2017 article-title: CXCL12/CXCR4 axis induced miR‐125b promotes invasion and confers 5‐fluorouracil resistance through enhancing autophagy in colorectal cancer publication-title: Sci Rep – volume: 8 start-page: 829 issue: 1 year: 2018 article-title: Exosome‐mediated breast cancer chemoresistance via miR‐155 transfer publication-title: Sci Rep – volume: 135 start-page: 1356 issue: 6 year: 2014 end-page: 68 article-title: miR‐200c suppresses TGF‐beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer publication-title: Int J Cancer – volume: 51 start-page: 456 issue: 9 year: 2018 end-page: 61 article-title: miR‐363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail‐induced epithelial‐mesenchymal transition publication-title: BMB Reports – volume: 556 start-page: 463 issue: 7702 year: 2018 end-page: 8 article-title: Identification of the tumour transition states occurring during EMT publication-title: Nature – volume: 27 start-page: 1166 issue: 6 year: 2019 end-page: 82 article-title: miR‐577 Regulates TGF‐beta Induced Cancer Progression through a SDPR‐Modulated Positive‐Feedback Loop with ERK‐NF‐kappaB in Gastric Cancer publication-title: Mol Ther – volume: 116 start-page: 7353 issue: 15 year: 2019 end-page: 62 article-title: Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells publication-title: Proc Natl Acad Sci U S A – volume: 8 issue: 10 year: 2017 article-title: miR‐3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis publication-title: Cell Death Dis – volume: 6 start-page: 1384 issue: 6 year: 2016 end-page: 95 article-title: Synergistic reversal effect of epithelial‐to‐mesenchymal transition by miR‐223 inhibitor and genistein in gemcitabine‐resistant pancreatic cancer cells publication-title: Am J Cancer Res – volume: 9 start-page: 7583 issue: 25 year: 2019 end-page: 98 article-title: HBX‐induced miR‐5188 impairs FOXO1 to stimulate beta‐catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma publication-title: Theranostics – volume: 50 start-page: 3050 issue: 17 year: 2014 end-page: 67 article-title: MicroRNA‐451 induces epithelial‐mesenchymal transition in docetaxel‐resistant lung adenocarcinoma cells by targeting proto‐oncogene c‐Myc publication-title: Eur J Cancer – volume: 5 start-page: 862 issue: 11 year: 2014 end-page: 72 article-title: MicroRNA‐495 induces breast cancer cell migration by targeting JAM‐A publication-title: Protein Cell – volume: 53 start-page: 644 issue: 2 year: 2018 end-page: 58 article-title: MicroRNA‐125a‐5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway publication-title: Int J Oncol – volume: 123 start-page: 566 issue: 2 year: 2013 end-page: 79 article-title: MicroRNA‐374a activates Wnt/beta‐catenin signaling to promote breast cancer metastasis publication-title: J Clin Invest – volume: 16 start-page: 1821 issue: 2 year: 2018 end-page: 6 article-title: MicroRNA‐218 inhibits the migration, epithelial‐mesenchymal transition and cancer stem cell properties of prostate cancer cells publication-title: Oncol Lett – volume: 16 start-page: 887 issue: 1 year: 2016 article-title: miR‐199a‐5p confers tumor‐suppressive role in triple‐negative breast cancer publication-title: BMC Cancer – volume: 50 start-page: 812 issue: 10 year: 2011 end-page: 22 article-title: Identification of miR‐374a as a prognostic marker for survival in patients with early‐stage nonsmall cell lung cancer publication-title: Genes Chromosomes Cancer – volume: 26 start-page: 1066 issue: 4 year: 2018 end-page: 81 article-title: miR‐296‐3p Negatively Regulated by Nicotine Stimulates Cytoplasmic Translocation of c‐Myc via MK2 to Suppress Chemotherapy Resistance publication-title: Mol Ther – volume: 8 issue: 1 year: 2018 article-title: Novel oncogenic and chemoresistance‐inducing functions of resistin in ovarian cancer cells require miRNAs‐mediated induction of epithelial‐to‐mesenchymal transition publication-title: Sci Rep – volume: 101 start-page: 945 year: 2018 end-page: 52 article-title: GDPD5, a target of miR‐195‐5p, is associated with metastasis and chemoresistance in colorectal cancer publication-title: Biomed Pharmacother – volume: 7 start-page: 4202 issue: 1 year: 2017 article-title: A microRNA signature of response to erlotinib is descriptive of TGFbeta behaviour in NSCLC publication-title: Sci Rep – volume: 54 start-page: 991 issue: 3 year: 2019 end-page: 1000 article-title: MicroRNA‐200b and ‐301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells publication-title: Int J Oncol – volume: 124 start-page: 3003 issue: 7 year: 2014 end-page: 15 article-title: CRIPTO1 expression in EGFR‐mutant NSCLC elicits intrinsic EGFR‐inhibitor resistance publication-title: J Clin Invest – volume: 13 start-page: 444 issue: 2 year: 2014 end-page: 53 article-title: miR‐134/487b/655 cluster regulates TGF‐beta‐induced epithelial‐mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells publication-title: Mol Cancer Ther – volume: 147 year: 2019 article-title: miR‐140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme publication-title: Pharmacol Res – volume: 92 start-page: 571 issue: 6 year: 2014 end-page: 81 article-title: ZNF281/ZBP‐99: a new player in epithelial‐mesenchymal transition, stemness, and cancer publication-title: J Mol Med (Berl) – volume: 39 start-page: 48 issue: 1 year: 2019 article-title: Cancer cell reprogramming: a promising therapy converting malignancy to benignity publication-title: Cancer Commun (Lond) – volume: 106 start-page: 1357 year: 2018 end-page: 63 article-title: miR‐1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R publication-title: Biomed Pharmacother – volume: 18 issue: 1 year: 2019 article-title: Exosome‐transmitted miR‐128‐3p increase chemosensitivity of oxaliplatin‐resistant colorectal cancer publication-title: Mol Cancer – volume: 36 start-page: 48 issue: 1 year: 2017 article-title: iASPP induces EMT and cisplatin resistance in human cervical cancer through miR‐20a‐FBXL5/BTG3 signaling publication-title: J Exp Clin Cancer Res – volume: 38 start-page: 226 issue: 1 year: 2019 article-title: The TGFbeta‐miR‐499a‐SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell‐like cells publication-title: J Exp Clin Cancer Res – volume: 9 start-page: 547 issue: 5 year: 2018 article-title: MicroRNA‐125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy publication-title: Cell Death Dis – volume: 402 start-page: 1 year: 2017 end-page: 8 article-title: Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA‐205 publication-title: Cancer Lett – volume: 98 start-page: 414 issue: 3 year: 2013 end-page: 9 article-title: Transcriptional regulation of miR‐10a/b by TWIST‐1 in myelodysplastic syndromes publication-title: Haematologica – volume: 102 start-page: 59 year: 2018 end-page: 70 article-title: MicroRNA‐17 inhibition overcomes chemoresistance and suppresses epithelial‐mesenchymal transition through a DEDD‐dependent mechanism in gastric cancer publication-title: Int J Biochem Cell Biol – year: 2018 article-title: Up‐regulation of miR‐210 induced by a hypoxic microenvironment promotes breast cancer stem cells metastasis, proliferation, and self‐renewal by targeting E‐cadherin publication-title: FASEB J – volume: 13 start-page: 472 year: 2018 end-page: 82 article-title: lncRNA GAS5 Reverses EMT and Tumor Stem Cell‐Mediated Gemcitabine Resistance and Metastasis by Targeting miR‐221/SOCS3 in Pancreatic Cancer publication-title: Mol Ther Nucleic Acids – volume: 4 start-page: 2980 year: 2013 article-title: Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs publication-title: Nat Commun – volume: 292 start-page: 11466 issue: 27 year: 2017 end-page: 84 article-title: Tumor‐associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFbeta signaling publication-title: J Biol Chem – volume: 35 start-page: 204 year: 2018 end-page: 21 article-title: The miR 495‐UBE2C‐ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin‐resistant non‐small cell lung cancer cells publication-title: EBioMedicine – volume: 22 start-page: 347 issue: 5 year: 2010 end-page: 52 article-title: IL‐6: from its discovery to clinical applications publication-title: Int Immunol – volume: 15 start-page: 18 year: 2016 article-title: Regulation of epithelial‐mesenchymal transition through epigenetic and post‐translational modifications publication-title: Mol Cancer – volume: 39 start-page: 1034 issue: 6 year: 2018 end-page: 47 article-title: A miRNA‐200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial‐mesenchymal transition publication-title: Acta Pharmacol Sin – volume: 9 issue: 4 year: 2014 article-title: miR‐124 Radiosensitizes human colorectal cancer cells by targeting PRRX1 publication-title: PLoS One – volume: 26 start-page: 744 issue: 3 year: 2018 end-page: 54 article-title: miR‐145 Antagonizes SNAI1‐Mediated Stemness and Radiation Resistance in Colorectal Cancer publication-title: Mol Ther – volume: 21 start-page: 430 issue: 3 year: 2012 end-page: 46 article-title: Transient low doses of DNA‐demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells publication-title: Cancer Cell – volume: 7 start-page: 831 issue: 6 year: 2015 end-page: 47 article-title: ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat publication-title: EMBO Mol Med – volume: 23 start-page: 171 issue: 2 year: 2013 end-page: 85 article-title: Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged‐1 publication-title: Cancer Cell – volume: 18 start-page: 320 year: 2019 end-page: 31 article-title: miR‐374a‐5p: A New Target for Diagnosis and Drug Resistance Therapy in Gastric Cancer publication-title: Mol Ther Nucleic Acids – volume: 63 start-page: 219 issue: 2 year: 2009 end-page: 26 article-title: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non‐small cell lung cancer cell line publication-title: Lung Cancer – volume: 28 start-page: 313 issue: 1 year: 2020 end-page: 27 article-title: Timeless‐Stimulated miR‐5188‐FOXO1/beta‐Catenin‐c‐Jun Feedback Loop Promotes Stemness via Ubiquitination of beta‐Catenin in Breast Cancer publication-title: Mol Ther – year: 2019 article-title: miR‐146b Reverses epithelial‐mesenchymal transition via targeting PTP1B in cisplatin‐resistance human lung adenocarcinoma cells publication-title: J Cell Biochem – year: 2020 article-title: The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction publication-title: Int J Cancer – volume: 11 start-page: 792 issue: 7 year: 2017 end-page: 804 article-title: Revisiting epithelial‐mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness publication-title: Mol Oncol – volume: 39 start-page: 542 issue: 4 year: 2018 end-page: 51 article-title: Exosomal cargo‐loading and synthetic exosome‐mimics as potential therapeutic tools publication-title: Acta Pharmacol Sin – volume: 7 issue: 2 year: 2012 article-title: Hypoxia‐induced down‐regulation of microRNA‐34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells publication-title: PLoS One – volume: 13 start-page: 11 issue: 1 year: 2020 article-title: CD73 sustained cancer‐stem‐cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma publication-title: J Hematol Oncol – volume: 13 start-page: 184 issue: 2 year: 2014 end-page: 91 article-title: FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial‐mesenchymal transition publication-title: Hepatobiliary Pancreat Dis Int – volume: 11 start-page: 252 issue: 4 year: 2010 end-page: 63 article-title: MicroRNA control of signal transduction publication-title: Nat Rev Mol Cell Biol – volume: 15 start-page: 2936 issue: 13 year: 2019 end-page: 47 article-title: miR‐4319 induced an inhibition of epithelial‐mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1 publication-title: Int J Biol Sci – volume: 7 start-page: 628 issue: 3 year: 2017 end-page: 46 article-title: miR‐495 promotes the chemoresistance of SCLC through the epithelial‐mesenchymal transition via Etk/BMX publication-title: Am J Cancer Res – volume: 37 start-page: 4300 issue: 31 year: 2018 end-page: 12 article-title: Epigenetic silencing of miR‐483‐3p promotes acquired gefitinib resistance and EMT in EGFR‐mutant NSCLC by targeting integrin beta3 publication-title: Oncogene – volume: 22 start-page: 108 issue: 3 year: 2015 end-page: 14 article-title: miR‐15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells publication-title: Cancer Gene Ther – volume: 38 start-page: 358 issue: 1 year: 2019 article-title: miR‐504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7‐mediated Wnt‐beta‐catenin pathway publication-title: J Exp Clin Cancer Res – volume: 18 start-page: 44 issue: Suppl 3 year: 2017 article-title: Identifying miRNA sponge modules using biclustering and regulatory scores publication-title: BMC Bioinformatics – volume: 291 issue: 43 year: 2016 article-title: MicroRNA‐155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer publication-title: J Biol Chem – volume: 20 start-page: 4257 issue: 20 year: 2016 end-page: 65 article-title: miR‐129‐5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial‐mesenchymal transition and multi‐drug resistance publication-title: Eur Rev Med Pharmacol Sci – volume: 40 start-page: 83 issue: 1 year: 2017 end-page: 9 article-title: hsa‐miR‐485‐5p reverses epithelial to mesenchymal transition and promotes cisplatin‐induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma publication-title: Int J Mol Med – volume: 7 start-page: 3948 issue: 16 year: 2017 end-page: 61 article-title: Aptamer‐Based Therapeutic Approaches to Target Cancer Stem Cells publication-title: Theranostics – volume: 9 year: 2019 article-title: Exosomes in Head and Neck Squamous Cell Carcinoma publication-title: Front Oncol – volume: 12 start-page: 86 issue: 1 year: 2014 end-page: 100 article-title: Maintenance of the stemness in CD44(+) HCT‐15 and HCT‐116 human colon cancer cells requires miR‐203 suppression publication-title: Stem Cell Res – volume: 259 start-page: 346 issue: 2 year: 2014 end-page: 54 article-title: Expression profile of microRNA‐200 family in hepatocellular carcinoma with bile duct tumor thrombus publication-title: Ann Surg – volume: 367 issue: 6478 year: 2020 article-title: The biology, function, and biomedical applications of exosomes publication-title: Science – volume: 23 start-page: 2442 issue: 4 year: 2019 end-page: 56 article-title: An integrated analysis to predict micro‐RNAs targeting both stemness and metastasis in breast cancer stem cells publication-title: J Cell Mol Med – volume: 13 start-page: 395 year: 2018 end-page: 412 article-title: Epithelial Mesenchymal Transition in Tumor Metastasis publication-title: Annu Rev Pathol – volume: 17 start-page: 1061 issue: 5 year: 2018 end-page: 9 article-title: MicroRNA‐203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial‐to‐mesenchymal Transition Pathway in Renal Cell Carcinoma publication-title: Mol Cancer Ther – volume: 34 start-page: 517 issue: 4 year: 2015 end-page: 30 article-title: Antithetical NFATc1‐Sox2 and p53‐miR200 signaling networks govern pancreatic cancer cell plasticity publication-title: EMBO J – volume: 14 start-page: 1715 issue: 3 year: 2013 end-page: 20 article-title: Effects of differential distribution of microvessel density, possibly regulated by miR‐374a, on breast cancer prognosis publication-title: Asian Pac J Cancer Prev – volume: 240 start-page: 1071 issue: 8 year: 2015 end-page: 8 article-title: MicroRNAs targeting prostate cancer stem cells publication-title: Exp Biol Med (Maywood) – volume: 62 start-page: 801 issue: 3 year: 2015 end-page: 15 article-title: MicroRNA‐125b attenuates epithelial‐mesenchymal transitions and targets stem‐like liver cancer cells through small mothers against decapentaplegic 2 and 4 publication-title: Hepatology – volume: 109 start-page: 19397 issue: 47 year: 2012 end-page: 402 article-title: miR‐495 is a tumor‐suppressor microRNA down‐regulated in MLL‐rearranged leukemia publication-title: Proc Natl Acad Sci U S A – volume: 18 start-page: 42 issue: 1 year: 2019 article-title: MCT‐1/miR‐34a/IL‐6/IL‐6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple‐negative breast cancer publication-title: Mol Cancer – volume: 710 start-page: 103 year: 2019 end-page: 13 article-title: miR‐205‐5p regulates epithelial‐mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin‐resistant nasopharyngeal carcinoma cells publication-title: Gene – volume: 10 start-page: 1888 issue: 12 year: 2011 end-page: 9 article-title: Vitamin D: a new player in the world of mTOR signaling publication-title: Cell Cycle – volume: 28 start-page: 6773 issue: 22 year: 2008 end-page: 84 article-title: MicroRNA‐155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA publication-title: Mol Cell Biol – volume: 22 start-page: 5490 issue: 17 year: 2018 end-page: 8 article-title: The increase of miR‐27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells publication-title: Eur Rev Med Pharmacol Sci – volume: 44 start-page: 117 year: 2017 end-page: 31 article-title: Role of miRNAs in human cancer metastasis: Implications for therapeutic intervention publication-title: Semin Cancer Biol – volume: 13 start-page: 2 issue: 1 year: 2020 article-title: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3beta signaling pathway in renal cell carcinoma publication-title: J Hematol Oncol – volume: 7 start-page: 2485 issue: 6 year: 2018 end-page: 503 article-title: miR‐21 improves invasion and migration of drug‐resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1 publication-title: Cancer Med – volume: 68 start-page: 3033 issue: 18 year: 2011 end-page: 46 article-title: Vimentin in cancer and its potential as a molecular target for cancer therapy publication-title: Cell Mol Life Sci – volume: 11 start-page: 64 issue: 1 year: 2018 article-title: The biology and role of CD44 in cancer progression: therapeutic implications publication-title: J Hematol Oncol – volume: 2 year: 2011 article-title: Transcription factors that mediate epithelial‐mesenchymal transition lead to multidrug resistance by upregulating ABC transporters publication-title: Cell Death Dis – volume: 138 start-page: 763 issue: 5 year: 2012 end-page: 74 article-title: MicroRNA‐223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4 publication-title: J Cancer Res Clin Oncol – volume: 9 start-page: 29906 issue: 52 year: 2018 end-page: 20 article-title: A mechanism‐based computational model to capture the interconnections among epithelial‐mesenchymal transition, cancer stem cells and Notch‐Jagged signaling publication-title: Oncotarget – volume: 6 start-page: 25161 issue: 28 year: 2015 end-page: 74 article-title: Coupling the modules of EMT and stemness: A tunable ‘stemness window’ model publication-title: Oncotarget – volume: 118 start-page: 4772 issue: 12 year: 2017 end-page: 81 article-title: Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial‐Mesenchymal Transition in Osteosarcoma by Regulating the miR‐221/ARHI Pathway publication-title: J Cell Biochem – volume: 25 start-page: 68 issue: 3‐4 year: 2018 end-page: 76 article-title: miR‐200c inhibits TGF‐beta‐induced‐EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer publication-title: Cancer Gene Ther – volume: 13 start-page: 2713 issue: 11 year: 2014 end-page: 26 article-title: SNAI2 modulates colorectal cancer 5‐fluorouracil sensitivity through miR145 repression publication-title: Mol Cancer Ther – volume: 106 start-page: 523 year: 2018 end-page: 31 article-title: miR‐125a‐3p is responsible for chemosensitivity in PDAC by inhibiting epithelial‐mesenchymal transition via Fyn publication-title: Biomed Pharmacother – volume: 652 start-page: 48 year: 2018 end-page: 58 article-title: MicroRNA‐139‐5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial‐to‐mesenchymal transition publication-title: Gene – volume: 74 start-page: 3995 issue: 14 year: 2014 end-page: 4005 article-title: The TGFβ‐miR200‐MIG6 pathway orchestrates the EMT‐associated kinase switch that induces resistance to EGFR inhibitors publication-title: Cancer Res – volume: 32 start-page: 5614 issue: 50 year: 2013 end-page: 24 article-title: miR‐155‐mediated loss of C/EBPbeta shifts the TGF‐beta response from growth inhibition to epithelial‐mesenchymal transition, invasion and metastasis in breast cancer publication-title: Oncogene – volume: 111 start-page: 478 issue: 3 year: 2008 end-page: 86 article-title: Role of microRNAs in drug‐resistant ovarian cancer cells publication-title: Gynecol Oncol – volume: 35 start-page: 19 year: 2016 article-title: miR‐130a‐3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells publication-title: J Exp Clin Cancer Res – volume: 43 start-page: 1617 issue: 4 year: 2017 end-page: 26 article-title: Astragaloside IV Induced miR‐134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW‐480 publication-title: Cell Physiol Biochem – volume: 5 start-page: 1268 issue: 6 year: 2016 end-page: 78 article-title: Role of cancer stem cells in racial disparity in colorectal cancer publication-title: Cancer Med – volume: 74 start-page: 3995 issue: 14 year: 2014 end-page: 4005 article-title: The TGFbeta‐miR200‐MIG6 pathway orchestrates the EMT‐associated kinase switch that induces resistance to EGFR inhibitors publication-title: Cancer Res – volume: 13 start-page: 15 issue: 1 year: 2020 article-title: NoncoRNA: a database of experimentally supported non‐coding RNAs and drug targets in cancer publication-title: J Hematol Oncol – volume: 11 start-page: 726 issue: 10 year: 2011 end-page: 34 article-title: A decade of exploring the cancer epigenome ‐ biological and translational implications publication-title: Nat Rev Cancer – volume: 47 start-page: 1533 issue: 4 year: 2018 end-page: 45 article-title: Sensitization of Gastric Cancer Cells to 5‐FU by MicroRNA‐204 Through Targeting the TGFBR2‐Mediated Epithelial to Mesenchymal Transition publication-title: Cell Physiol Biochem – volume: 31 start-page: 634 issue: 5 year: 2012 end-page: 42 article-title: miR‐130a targets MET and induces TRAIL‐sensitivity in NSCLC by downregulating miR‐221 and 222 publication-title: Oncogene – volume: 8 issue: 10 year: 2017 article-title: miR‐99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer publication-title: Cell Death Dis – volume: 447 start-page: 210 issue: 1 year: 2014 end-page: 5 article-title: miR‐612 suppresses the stemness of liver cancer via Wnt/beta‐catenin signaling publication-title: Biochem Biophys Res Commun – volume: 466 start-page: 835 issue: 7308 year: 2010 end-page: 40 article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels publication-title: Nature – volume: 9 start-page: 1678 issue: 8 year: 2015 end-page: 93 article-title: The miR‐200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR‐3 and MES‐OV cells publication-title: Mol Oncol – volume: 65 start-page: 9455 issue: 20 year: 2005 end-page: 62 article-title: Epithelial to mesenchymal transition is a determinant of sensitivity of non‐small‐cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition publication-title: Cancer Res – volume: 43 start-page: 7 year: 2016 end-page: 13 article-title: Epithelial‐mesenchymal transition (EMT) and metastasis: yes, no, maybe? publication-title: Curr Opin Cell Biol – volume: 11 start-page: 9 issue: 1 year: 2018 article-title: The polycomb group protein EZH2 induces epithelial‐mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter publication-title: J Hematol Oncol – volume: 8 issue: 3 year: 2013 article-title: RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy publication-title: PLoS One – volume: 8 issue: 10 year: 2019 article-title: The E‐Cadherin and N‐Cadherin Switch in Epithelial‐to‐Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges publication-title: Cells – volume: 41 start-page: 973 issue: 3 year: 2017 end-page: 86 article-title: A Feedback Loop Between miR‐30a/c‐5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells publication-title: Cell Physiol Biochem – volume: 126 start-page: 2867 year: 2013 end-page: 76 article-title: microRNA‐125a‐3p reduces cell proliferation and migration by targeting Fyn publication-title: J Cell Sci – volume: 54 start-page: 326 issue: 1 year: 2019 end-page: 38 article-title: Paclitaxelresistant gastric cancer MGC803 cells promote epithelialtomesenchymal transition and chemoresistance in paclitaxelsensitive cells via exosomal delivery of miR1555p publication-title: Int J Oncol – volume: 116 start-page: 281 issue: 2 year: 2004 end-page: 97 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 109 start-page: 1404 issue: 5 year: 2018 end-page: 13 article-title: MicroRNA‐708‐3p mediates metastasis and chemoresistance through inhibition of epithelial‐to‐mesenchymal transition in breast cancer publication-title: Cancer Sci – volume: 14 year: 2014 article-title: Co‐expression of putative stemness and epithelial‐to‐mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer publication-title: BMC Cancer – volume: 264 start-page: 804 issue: 5 year: 2016 end-page: 14 article-title: miR‐221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression publication-title: Ann Surg – volume: 32 start-page: 2341 issue: 11 year: 2017 end-page: 51 article-title: The mechanisms for lung cancer risk of PM2.5 : Induction of epithelial‐mesenchymal transition and cancer stem cell properties in human non‐small cell lung cancer cells publication-title: Environ Toxicol – volume: 12 issue: 1 year: 2019 article-title: LincK contributes to breast tumorigenesis by promoting proliferation and epithelial‐to‐mesenchymal transition publication-title: J Hematol Oncol – volume: 36 start-page: 1631 issue: 12 year: 2017 end-page: 43 article-title: miR‐127 promotes EMT and stem‐like traits in lung cancer through a feed‐forward regulatory loop publication-title: Oncogene – volume: 9 issue: 1 year: 2019 article-title: Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR‐375/oncogenes circuit publication-title: Sci Rep – volume: 433 start-page: 769 issue: 7027 year: 2005 end-page: 73 article-title: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs publication-title: Nature – volume: 124 start-page: 3093 issue: 7 year: 2014 end-page: 106 article-title: MicroRNA‐205 signaling regulates mammary stem cell fate and tumorigenesis publication-title: J Clin Invest – volume: 48 start-page: 937 issue: 3 year: 2016 end-page: 44 article-title: miR‐200/ZEB axis regulates sensitivity to nintedanib in non‐small cell lung cancer cells publication-title: Int J Oncol – volume: 6 year: 2016 article-title: miR‐139‐5p Inhibits the Epithelial‐Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2 publication-title: Sci Rep – volume: 18 issue: 4 year: 2017 article-title: Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis publication-title: Int J Mol Sci – volume: 22 start-page: 1686 issue: 10 year: 2011 end-page: 98 article-title: An autocrine TGF‐beta/ZEB/miR‐200 signaling network regulates establishment and maintenance of epithelial‐mesenchymal transition publication-title: Mol Biol Cell – volume: 9 start-page: 582 issue: 6 year: 2008 end-page: 9 article-title: A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cells publication-title: EMBO Rep – volume: 700 start-page: 110 year: 2019 end-page: 9 article-title: MicroRNA‐574‐3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells publication-title: Gene – volume: 16 start-page: 1954 issue: 20 year: 2017 end-page: 64 article-title: miR‐26b reverses temozolomide resistance via targeting Wee1 in glioma cells publication-title: Cell Cycle – volume: 37 start-page: 52 issue: 1 year: 2018 article-title: Exosomal microRNA‐32‐5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway publication-title: J Exp Clin Cancer Res – volume: 40 start-page: 341 issue: 3 year: 2014 end-page: 8 article-title: Epithelial‐to‐mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance publication-title: Cancer Treat Rev – volume: 21 start-page: 462 issue: 3 year: 2014 end-page: 74 article-title: The miR‐106b∼25 cluster promotes bypass of doxorubicin‐induced senescence and increase in motility and invasion by targeting the E‐cadherin transcriptional activator EP300 publication-title: Cell Death Differ – volume: 35 start-page: 132 issue: 1 year: 2016 article-title: miR‐137 and miR‐34a directly target Snail and inhibit EMT, invasion and sphere‐forming ability of ovarian cancer cells publication-title: J Exp Clin Cancer Res – volume: 36 start-page: 2577 issue: 18 year: 2017 end-page: 88 article-title: Downregulation of miR‐218 contributes to epithelial‐mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling publication-title: Oncogene – volume: 53 start-page: 232 year: 2018 end-page: 47 article-title: Current understanding and clinical utility of miRNAs regulation of colon cancer stem cells publication-title: Semin Cancer Biol – volume: 26 start-page: 774 issue: 3 year: 2018 end-page: 83 article-title: Exosomes Serve as Nanoparticles to Deliver Anti‐miR‐214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer publication-title: Mol Ther – volume: 285 start-page: 34439 issue: 45 year: 2010 end-page: 46 article-title: MicroRNA‐223 regulates cyclin E activity by modulating expression of F‐box and WD‐40 domain protein 7 publication-title: J Biol Chem – volume: 338 start-page: 120 issue: 1 year: 2013 end-page: 6 article-title: Regulation of intestinal cancer stem cells publication-title: Cancer Lett – volume: 234 start-page: 8274 issue: 6 year: 2019 end-page: 85 article-title: Stromal‐induced downregulation of miR‐1247 promotes prostate cancer malignancy publication-title: J Cell Physiol – volume: 108 start-page: 23 issue: 1 year: 2017 end-page: 31 article-title: miR‐25‐3p reverses epithelial‐mesenchymal transition via targeting Sema4C in cisplatin‐resistance cervical cancer cells publication-title: Cancer Sci – volume: 23 start-page: 6336 issue: 20 year: 2017 end-page: 50 article-title: miRomics and Proteomics Reveal a miR‐296‐3p/PRKCA/FAK/Ras/c‐Myc Feedback Loop Modulated by HDGF/DDX5/beta‐catenin Complex in Lung Adenocarcinoma publication-title: Clin Cancer Res – volume: 13 year: 2014 article-title: MCRS1 overexpression, which is specifically inhibited by miR‐129*, promotes the epithelial‐mesenchymal transition and metastasis in non‐small cell lung cancer publication-title: Mol Cancer – volume: 234 start-page: 8381 issue: 6 year: 2019 end-page: 95 article-title: Cancer stem cells (CSCs) in cancer progression and therapy publication-title: J Cell Physiol – volume: 70 start-page: 224 issue: 3 year: 2018 end-page: 36 article-title: The miR‐203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK‐3beta/beta‐CATENIN signal pathway publication-title: IUBMB Life – volume: 17 start-page: 648 issue: 5 year: 2016 end-page: 58 article-title: miR‐10b expression in breast cancer stem cells supports self‐renewal through negative PTEN regulation and sustained AKT activation publication-title: EMBO Rep – volume: 33 start-page: 786 issue: 6 year: 2011 end-page: 91 article-title: MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel‐induced multidrug resistance publication-title: Head Neck – volume: 527 start-page: 472 issue: 7579 year: 2015 end-page: 6 article-title: Epithelial‐to‐mesenchymal transition is not required for lung metastasis but contributes to chemoresistance publication-title: Nature – volume: 11 start-page: 8686 issue: 24 Pt 1 year: 2005 end-page: 98 article-title: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients publication-title: Clin Cancer Res – volume: 36 start-page: 5199 issue: 36 year: 2017 end-page: 211 article-title: VEGFA links self‐renewal and metastasis by inducing Sox2 to repress miR‐452, driving Slug publication-title: Oncogene – volume: 7 start-page: 4002 issue: 1 year: 2017 article-title: miR‐509‐5p and miR‐1243 increase the sensitivity to gemcitabine by inhibiting epithelial‐mesenchymal transition in pancreatic cancer publication-title: Sci Rep – volume: 11 issue: 10 year: 2019 article-title: High Expression of MicroRNA‐196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients publication-title: Cancers (Basel) – volume: 41 start-page: 583 issue: 2 year: 2017 end-page: 97 article-title: miRNA‐26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel‐Resistant Lung Adenocarcinoma Cells through Targeting EZH2 publication-title: Cell Physiol Biochem – volume: 8 start-page: 8704 issue: 1 year: 2018 article-title: Snail knockdown reverses stemness and inhibits tumour growth in ovarian cancer publication-title: Sci Rep – volume: 12 issue: 2 year: 2017 article-title: Chronic treatment of non‐small‐cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA‐155 and ‐200c publication-title: PLoS One – volume: 13 start-page: 12 issue: 1 year: 2020 article-title: miR‐612 regulates invadopodia of hepatocellular carcinoma by HADHA‐mediated lipid reprogramming publication-title: J Hematol Oncol – volume: 9 start-page: 687 issue: 6 year: 2018 article-title: The distinct role of strand‐specific miR‐514b‐3p and miR‐514b‐5p in colorectal cancer metastasis publication-title: Cell Death Dis – volume: 116 start-page: 1318 issue: 10 year: 2017 end-page: 28 article-title: Decreased levels of baseline and drug‐induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial‐to‐mesenchymal transition publication-title: Br J Cancer – volume: 70 start-page: 256 issue: 4 year: 2015 end-page: 62 article-title: Nobiletin inhibited hypoxia‐induced epithelial‐mesenchymal transition of lung cancer cells by inactivating of Notch‐1 signaling and switching on miR‐200b publication-title: Pharmazie – volume: 45 start-page: 995 issue: 12 year: 2013 end-page: 1001 article-title: Downregulation of miR‐130a contributes to cisplatin resistance in ovarian cancer cells by targeting X‐linked inhibitor of apoptosis (XIAP) directly publication-title: Acta Biochim Biophys Sin (Shanghai) – volume: 12 issue: 1 year: 2019 article-title: miR‐195‐5p/NOTCH2‐mediated EMT modulates IL‐4 secretion in colorectal cancer to affect M2‐like TAM polarization publication-title: Journal of Hematology & Oncology – volume: 36 start-page: 275 issue: 2 year: 2017 end-page: 85 article-title: miR‐374a‐CCND1‐pPI3K/AKT‐c‐JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin publication-title: Oncogene – ident: e_1_2_9_122_1 doi: 10.1074/jbc.M110.152306 – ident: e_1_2_9_64_1 doi: 10.1016/j.ymthe.2019.08.015 – ident: e_1_2_9_127_1 doi: 10.1159/000482025 – ident: e_1_2_9_93_1 doi: 10.1016/j.lungcan.2008.05.017 – ident: e_1_2_9_14_1 doi: 10.1186/s40880-019-0393-5 – ident: e_1_2_9_84_1 doi: 10.3892/ijo.2016.3331 – ident: e_1_2_9_158_1 doi: 10.1126/science.aau6977 – volume: 6 start-page: 1384 issue: 6 year: 2016 ident: e_1_2_9_125_1 article-title: Synergistic reversal effect of epithelial‐to‐mesenchymal transition by miR‐223 inhibitor and genistein in gemcitabine‐resistant pancreatic cancer cells publication-title: Am J Cancer Res – ident: e_1_2_9_105_1 doi: 10.1016/j.molonc.2015.04.015 – ident: e_1_2_9_109_1 doi: 10.1038/cddis.2011.61 – ident: e_1_2_9_164_1 doi: 10.1038/onc.2013.322 – ident: e_1_2_9_67_1 doi: 10.1186/s13045-017-0547-3 – ident: e_1_2_9_27_1 doi: 10.1073/pnas.1812876116 – ident: e_1_2_9_103_1 doi: 10.1159/000460618 – ident: e_1_2_9_90_1 doi: 10.1186/1476-4598-13-245 – ident: e_1_2_9_85_1 doi: 10.1158/0008-5472.CAN-14-0110 – ident: e_1_2_9_100_1 doi: 10.1159/000490871 – ident: e_1_2_9_167_1 doi: 10.1016/j.omtn.2019.07.025 – ident: e_1_2_9_155_1 doi: 10.3892/ijmm.2017.2992 – ident: e_1_2_9_54_1 doi: 10.1007/s00109-014-1160-3 – ident: e_1_2_9_16_1 doi: 10.7150/thno.20725 – ident: e_1_2_9_42_1 doi: 10.1002/jcp.27679 – ident: e_1_2_9_52_1 doi: 10.1002/tox.22437 – ident: e_1_2_9_37_1 doi: 10.3892/ol.2018.8877 – ident: e_1_2_9_152_1 doi: 10.1080/15384101.2017.1367071 – ident: e_1_2_9_116_1 doi: 10.1186/s13046-016-0296-0 – ident: e_1_2_9_129_1 doi: 10.1016/j.biopha.2018.03.028 – ident: e_1_2_9_135_1 doi: 10.3892/ijo.2019.4676 – ident: e_1_2_9_11_1 doi: 10.1038/nature03315 – ident: e_1_2_9_48_1 doi: 10.1016/j.scr.2013.09.011 – ident: e_1_2_9_22_1 doi: 10.1038/nrm2868 – ident: e_1_2_9_33_1 doi: 10.1016/j.ymthe.2017.12.023 – ident: e_1_2_9_97_1 doi: 10.1002/cam4.1294 – ident: e_1_2_9_162_1 doi: 10.3892/ijo.2018.4601 – ident: e_1_2_9_44_1 doi: 10.15252/emmm.201404396 – ident: e_1_2_9_168_1 doi: 10.1016/j.ymthe.2018.01.001 – ident: e_1_2_9_29_1 doi: 10.1002/jcp.27740 – ident: e_1_2_9_83_1 doi: 10.1091/mbc.E11-02-0103 – ident: e_1_2_9_79_1 doi: 10.1073/pnas.1217519109 – ident: e_1_2_9_115_1 doi: 10.1038/s41419-018-0592-z – ident: e_1_2_9_107_1 doi: 10.1111/cas.13104 – volume: 20 start-page: 4257 issue: 20 year: 2016 ident: e_1_2_9_110_1 article-title: miR‐129‐5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial‐mesenchymal transition and multi‐drug resistance publication-title: Eur Rev Med Pharmacol Sci – volume: 70 start-page: 256 issue: 4 year: 2015 ident: e_1_2_9_126_1 article-title: Nobiletin inhibited hypoxia‐induced epithelial‐mesenchymal transition of lung cancer cells by inactivating of Notch‐1 signaling and switching on miR‐200b publication-title: Pharmazie – ident: e_1_2_9_172_1 doi: 10.1038/srep40847 – ident: e_1_2_9_118_1 doi: 10.1038/s41598-019-48081-9 – ident: e_1_2_9_34_1 doi: 10.1186/s12885-016-2916-7 – ident: e_1_2_9_98_1 doi: 10.1038/onc.2016.332 – ident: e_1_2_9_139_1 doi: 10.1159/000503225 – ident: e_1_2_9_4_1 doi: 10.1038/nature15748 – ident: e_1_2_9_133_1 doi: 10.1371/journal.pone.0093917 – ident: e_1_2_9_120_1 doi: 10.1186/s13045-019-0841-3 – ident: e_1_2_9_35_1 doi: 10.1016/j.ccr.2012.12.021 – volume: 7 start-page: 628 issue: 3 year: 2017 ident: e_1_2_9_80_1 article-title: miR‐495 promotes the chemoresistance of SCLC through the epithelial‐mesenchymal transition via Etk/BMX publication-title: Am J Cancer Res – ident: e_1_2_9_88_1 doi: 10.1371/journal.pone.0172115 – ident: e_1_2_9_92_1 doi: 10.1158/0008-5472.Can-05-1058 – ident: e_1_2_9_70_1 doi: 10.1093/abbs/gmt113 – ident: e_1_2_9_74_1 doi: 10.1172/JCI73048 – ident: e_1_2_9_40_1 doi: 10.1186/s12859-017-1467-5 – ident: e_1_2_9_111_1 doi: 10.1002/ijc.28782 – ident: e_1_2_9_174_1 doi: 10.5483/BMBRep.2018.51.9.104 – ident: e_1_2_9_124_1 doi: 10.1016/s1499-3872(14)60029-1 – ident: e_1_2_9_82_1 doi: 10.1038/embor.2008.74 – ident: e_1_2_9_146_1 doi: 10.1016/j.ymthe.2018.01.023 – ident: e_1_2_9_170_1 doi: 10.1016/j.canlet.2017.05.007 – ident: e_1_2_9_69_1 doi: 10.1002/hed.21540 – ident: e_1_2_9_104_1 doi: 10.1016/j.biopha.2018.07.059 – ident: e_1_2_9_161_1 doi: 10.3389/fonc.2019.00894 – ident: e_1_2_9_49_1 doi: 10.1038/s41598-018-30978-6 – ident: e_1_2_9_106_1 doi: 10.1038/bjc.2017.102 – ident: e_1_2_9_31_1 doi: 10.1177/1535370215584935 – ident: e_1_2_9_60_1 doi: 10.1096/fj.201801013R – ident: e_1_2_9_61_1 doi: 10.1016/j.ymthe.2019.02.002 – ident: e_1_2_9_159_1 doi: 10.1038/aps.2017.178 – ident: e_1_2_9_140_1 doi: 10.1002/jcb.26145 – ident: e_1_2_9_123_1 doi: 10.1007/s00432-012-1154-x – ident: e_1_2_9_87_1 doi: 10.1038/s41598-017-04097-7 – ident: e_1_2_9_147_1 doi: 10.1016/j.gene.2019.05.058 – ident: e_1_2_9_149_1 doi: 10.1172/jci65871 – ident: e_1_2_9_6_1 doi: 10.1007/s00018-011-0735-1 – ident: e_1_2_9_59_1 doi: 10.15252/embr.201540678 – ident: e_1_2_9_154_1 doi: 10.1242/jcs.123414 – ident: e_1_2_9_7_1 doi: 10.1371/journal.pone.0030771 – ident: e_1_2_9_45_1 doi: 10.1158/1535-7163.MCT-17-0925 – ident: e_1_2_9_145_1 doi: 10.1016/j.gene.2018.02.003 – ident: e_1_2_9_2_1 doi: 10.1186/s12943-016-0502-x – ident: e_1_2_9_5_1 doi: 10.3390/cells8101118 – ident: e_1_2_9_113_1 doi: 10.1111/cas.13588 – ident: e_1_2_9_46_1 doi: 10.1186/s13045-019-0840-4 – ident: e_1_2_9_53_1 doi: 10.1186/s12943-019-0988-0 – ident: e_1_2_9_117_1 doi: 10.4161/cc.10.12.15620 – ident: e_1_2_9_55_1 doi: 10.1097/SLA.0000000000000223 – ident: e_1_2_9_43_1 doi: 10.7150/ijbs.38000 – ident: e_1_2_9_68_1 doi: 10.1016/j.ygyno.2008.08.017 – ident: e_1_2_9_141_1 doi: 10.1016/j.omtn.2018.09.026 – ident: e_1_2_9_136_1 doi: 10.1038/cddis.2017.530 – ident: e_1_2_9_36_1 doi: 10.1172/JCI73351 – ident: e_1_2_9_143_1 doi: 10.1093/intimm/dxq030 – ident: e_1_2_9_112_1 doi: 10.1186/s13045-019-0707-8 – ident: e_1_2_9_160_1 doi: 10.1038/ncomms3980 – ident: e_1_2_9_165_1 doi: 10.1074/jbc.A110.101055 – ident: e_1_2_9_20_1 doi: 10.1186/1471-2407-14-651 – ident: e_1_2_9_76_1 doi: 10.1016/j.ejca.2014.09.008 – ident: e_1_2_9_99_1 doi: 10.1038/s41417-017-0005-y – ident: e_1_2_9_128_1 doi: 10.1038/srep27157 – ident: e_1_2_9_57_1 doi: 10.3324/haematol.2012.071753 – ident: e_1_2_9_32_1 doi: 10.1002/hep.27887 – ident: e_1_2_9_176_1 doi: 10.26355/eurrev_201809_15809 – ident: e_1_2_9_77_1 doi: 10.1038/s41388-018-0276-2 – ident: e_1_2_9_51_1 doi: 10.1038/s41598-018-27021-z – ident: e_1_2_9_58_1 doi: 10.1074/jbc.M117.775080 – volume: 68 start-page: 955 issue: 12 year: 2013 ident: e_1_2_9_175_1 article-title: Let‐7c sensitizes acquired cisplatin‐resistant A549 cells by targeting ABCC2 and Bcl‐XL publication-title: Pharmazie – ident: e_1_2_9_144_1 doi: 10.1097/sla.0000000000001928 – ident: e_1_2_9_24_1 doi: 10.3390/ijms18040890 – ident: e_1_2_9_114_1 doi: 10.1038/cdd.2013.167 – ident: e_1_2_9_171_1 doi: 10.1016/j.biopha.2018.06.114 – ident: e_1_2_9_18_1 doi: 10.1186/s13045-018-0605-5 – ident: e_1_2_9_9_1 doi: 10.1146/annurev-pathol-020117-043854 – ident: e_1_2_9_177_1 doi: 10.3390/cancers11101549 – ident: e_1_2_9_3_1 doi: 10.1002/1878-0261.12096 – ident: e_1_2_9_13_1 doi: 10.1016/j.semcancer.2017.02.004 – ident: e_1_2_9_78_1 doi: 10.1007/s13238-014-0088-2 – ident: e_1_2_9_173_1 doi: 10.1158/0008-5472.Can-14-0110 – ident: e_1_2_9_10_1 doi: 10.1016/s0092-8674(04)00045-5 – ident: e_1_2_9_75_1 doi: 10.1158/1078-0432.CCR-16-2813 – ident: e_1_2_9_91_1 doi: 10.1158/1078-0432.Ccr-05-1492 – ident: e_1_2_9_138_1 doi: 10.1016/j.ccr.2011.12.029 – ident: e_1_2_9_25_1 doi: 10.1038/s41586-018-0040-3 – ident: e_1_2_9_81_1 doi: 10.1016/j.ebiom.2018.08.001 – ident: e_1_2_9_19_1 doi: 10.1016/j.semcancer.2018.08.003 – ident: e_1_2_9_38_1 doi: 10.1038/onc.2017.4 – ident: e_1_2_9_169_1 doi: 10.1186/s13045-020-00849-7 – ident: e_1_2_9_66_1 doi: 10.1159/000457879 – ident: e_1_2_9_21_1 doi: 10.1186/s13045-020-0845-z – ident: e_1_2_9_23_1 doi: 10.1016/j.canlet.2012.04.016 – ident: e_1_2_9_63_1 doi: 10.7150/thno.37717 – ident: e_1_2_9_30_1 doi: 10.1038/cddis.2017.544 – ident: e_1_2_9_156_1 doi: 10.1186/s13046-019-1195-y – ident: e_1_2_9_56_1 doi: 10.15252/embj.201489574 – ident: e_1_2_9_94_1 doi: 10.1158/1535-7163.Mct-13-0448 – ident: e_1_2_9_50_1 doi: 10.1186/s13046-016-0415-y – ident: e_1_2_9_71_1 doi: 10.1038/onc.2011.260 – ident: e_1_2_9_142_1 doi: 10.3892/ijo.2018.4409 – ident: e_1_2_9_134_1 doi: 10.1038/s41598-017-04191-w – ident: e_1_2_9_101_1 doi: 10.1016/j.gene.2019.03.043 – ident: e_1_2_9_108_1 doi: 10.1016/j.ctrv.2013.09.008 – ident: e_1_2_9_26_1 doi: 10.18632/oncotarget.4629 – ident: e_1_2_9_137_1 doi: 10.1038/nrc3130 – ident: e_1_2_9_150_1 doi: 10.1002/gcc.20902 – ident: e_1_2_9_96_1 doi: 10.1371/journal.pone.0059104 – ident: e_1_2_9_119_1 doi: 10.1016/j.bbrc.2014.03.135 – ident: e_1_2_9_86_1 doi: 10.1038/aps.2017.164 – ident: e_1_2_9_121_1 doi: 10.1186/s13046-018-0677-7 – ident: e_1_2_9_131_1 doi: 10.1158/1535-7163.MCT-14-0207 – ident: e_1_2_9_41_1 doi: 10.1038/s41419-018-0732-5 – ident: e_1_2_9_148_1 doi: 10.1038/onc.2016.201 – ident: e_1_2_9_153_1 doi: 10.1016/j.phrs.2019.104390 – ident: e_1_2_9_89_1 doi: 10.1128/mcb.00941-08 – ident: e_1_2_9_65_1 doi: 10.1186/s13046-017-0520-6 – ident: e_1_2_9_166_1 doi: 10.1186/s12943-019-0981-7 – ident: e_1_2_9_62_1 doi: 10.1002/cam4.690 – ident: e_1_2_9_47_1 doi: 10.1002/iub.1720 – ident: e_1_2_9_8_1 doi: 10.1016/j.ceb.2016.06.002 – ident: e_1_2_9_163_1 doi: 10.1038/s41598-018-19339-5 – ident: e_1_2_9_39_1 doi: 10.1186/s13046-019-1370-1 – ident: e_1_2_9_73_1 doi: 10.1038/onc.2016.414 – ident: e_1_2_9_132_1 doi: 10.1038/srep42226 – ident: e_1_2_9_102_1 doi: 10.1016/j.biocel.2018.06.007 – ident: e_1_2_9_157_1 doi: 10.1002/ijc.33386 – ident: e_1_2_9_28_1 doi: 10.18632/oncotarget.25692 – ident: e_1_2_9_72_1 doi: 10.1002/jcb.29554 – ident: e_1_2_9_130_1 doi: 10.1186/s13045-019-0708-7 – ident: e_1_2_9_151_1 doi: 10.7314/apjcp.2013.14.3.1715 – ident: e_1_2_9_12_1 doi: 10.1038/nature09267 – ident: e_1_2_9_17_1 doi: 10.1016/j.semcancer.2018.08.008 – ident: e_1_2_9_15_1 doi: 10.1111/jcmm.14090 – ident: e_1_2_9_95_1 doi: 10.1038/cgt.2014.73 |
| SSID | ssj0001989453 |
| Score | 2.5941956 |
| SecondaryResourceType | review_article |
| Snippet | Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis.... Epithelial-to-mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and metastasis.... Abstract Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant behaviors of cancers, including proliferation, invasion, and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 199 |
| SubjectTerms | Binding sites Breast cancer cancer cancer stem cell cancer stemness Colorectal cancer Cytokines Drug resistance Epidermal growth factor epithelial‐to‐mesenchymal transition Esophageal cancer Gastric cancer Gene expression Kinases Liver cancer Lung cancer Medical prognosis Metastasis microRNA MicroRNAs Ovarian cancer Pancreatic cancer Prostate cancer Proteins Review Stem cells Throat cancer Transcription factors Tumors Vascular endothelial growth factor |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQ1QMXBOIvUJAruIAU1fFvfFxWrXphBWgPvVm2M4aVIEW7Xc48As_IkzB20mhXreDCLYonkjPjyXwTj78h5HUKSluwbQ0YXmuZINatTrY2gVsD0uI6CaXZhFks2osL-2Gn1VeuCRvogQfFnTQQk-3A69aDDA1Yz6IRHHhSXrFQEh9EPTvJVPm7knnFlZj4SPlJ9JFnKoV8EGUnAhWi_tvQ5c0iyV3wWqLP2X1yb4SNdDZM9wG5A_1D8vH0_fL3z19-1DB09Fsur_u0mG2o7ztaNgForh_c0FVPYzbwmmbm5vx9KyLdevuZYsadUSSOPiLLs9Pl_LweWyTUUWGoraEBzHh4Cp3SEEVA9CWtEDoYSMFLlpjypbdGUAFsI8BwISJG5c7IAEw8Jgf9ZQ9PCe260NjAQwLNpOfaI5A1HnNn5tFrPVTkzbXWXBzpw3MXi69uID7mLmvYFQ1X5NUk-30gzbhV6l1W_iSRia7LDTS_G83v_mX-ihxdm86N3rdx-YwdIiUhbEWOp2H0m7wZ4nu43KKMxMRKc8t4RZ4Mlp5mIoRCJMZkRczeGtib6v5Iv_pSuLmN1W3b4pNvy2r5y-u7-WzOy9Wz_6GI5-Quz-U2pTzuiBxcrbfwghzGH1erzfpl8Y4_6bIWeQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Wiley Online Library Open Access dbid: 24P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB6VwoELP-IvUJARXECKmthOHEtcllUrLqwK2kNvlu1MykqQRUmXM4_AM_IkjJ1slhUVEuKUKB5LiT3j-cYZfwPwsnFFqVFXKZJ7TWWDPq3KRqfKca1QatITF4tNqMWiOj_XZwfwZnsWZuCHmDbcgmXE9ToYuHX98Y401FvPAzeCqK7B9ZwuoXADl2e7HZbALR5pKDlFW6kgbD7xk_LjXfc9jxSJ-69Cm38mTf4OZqM3Or39f99xB26NKJTNBrW5CwfY3oMPJ--XP7__sOOEYc2-hGy9j4tZz2xbs_hPgYV0xJ6tWuaDvnQsEEGH5TKK1N3mglEAH0Aptd6H5enJcv4uHSsupL4gz51ijhRA8cbVRYleOAJzUgtROoWNszJrssLGUh2ucKhzgYoL4cnJ10o6zMQDOGzXLT4CVtcu1467BstMWl5awsXKUiieWVoELCbwajvoxo9s5KEoxmcz8ChzE8bFxHFJ4MUk-3Xg4LhS6m2Yu0ki8GbHB-vuwoxmaHL0ja7RlpVF6XLUNvNKcORNYYvM5QkcbWfejMbcm3Bkj4CXEDqB51MzmWH4t2JbXG9IRlKcVnKd8QQeDooyvYkQBQG7TCag9lRo71X3W9rVp0j1rXRZVRX1fB1V6C-fb-azOY93j_9F-Anc5CFLJ2bVHcHhZbfBp3DDf7tc9d2zaFC_AJ3gInA priority: 102 providerName: Wiley-Blackwell |
| Title | EMT‐associated microRNAs and their roles in cancer stemness and drug resistance |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcac2.12138 https://www.ncbi.nlm.nih.gov/pubmed/33506604 https://www.proquest.com/docview/2702741339 https://www.proquest.com/docview/2482662902 https://pubmed.ncbi.nlm.nih.gov/PMC7968884 https://doaj.org/article/1ecf9dea68ae4b1e9a0c732e2f5a50b1 |
| Volume | 41 |
| WOSCitedRecordID | wos000614106100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: M~E dateStart: 20180101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: M0R dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: 7RV dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2523-3548 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001989453 issn: 2523-3548 databaseCode: 24P dateStart: 19970101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYygMvA8RXYFRB8AJStMRO4vgJdVUn9tAQVRWUp8h2LqMSpFuz8vdz56bZKqa98GI58UWyc3e-s33-HWMfapOkClQWAJrXIK7BBllaq0AariTECuXEuGQTMs-zxUIV3YZb24VV7uZEN1FXK0t75Cd0bwqtnxDq8-VVQFmj6HS1S6FxwAYR2W6UZzn7drPHQujiiehRSfmJ1ZYToAJdR7llhxxc_10-5r-hkrddWGeDzh7_b--fsKPO-_RHW3F5yh5A84x9nUznge7YBJX_m2L0Zvmo9XVT-e4kwacgxNZfNr4lKVn7BP9Mk6QjqdabCx-X7eSKYutzNj-bzMdfgi7PQmATtNcBRIDLJl6bKknBCoMuXKyESI2E2ug4rMNEuwQdJjGgIgGSC2HRtFcyNhCKF-ywWTXwivlVZSJluKkhDWPNU43esNS4AA81qr4Gj33c_fTSdhjklArjV7lFT-YlMah0DPLY-572cou8cSfVKfGupyC0bPditb4oO-UrI7C1qkCnmYbYRKB0aKXgwOtEJ6GJPHa841rZqXBb3rDMY-_6ZlQ-OlHRDaw2SBPj6izlKuQee7kVlL4nQiTozoWxx-SeCO11db-lWf50AN9SpVmW4ZefnLDdM_xyPBpzV3t9_xjesEeconFc9NwxO7xeb-Ate2j_XC_b9ZAd8LgYOuWhciFdmQ3Z4HSSF7Oh26nAchpifVCcT4sf-PT9PP8L7eoqPQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VggQXHgJKoIARcAApamIncXxAaFlatWq7ILSH3izbmZSVIFuSLogfxX_E481uu6LqrQduUTyJ4vjzPOzxNwCvapsXClUZozevcVaji8uiVrG0XEnMlMeJDcUm5GhUHh2pz2vwZ3EWhtIqFzoxKOpq6miNfIvOTXnrJ4R6f_IjpqpRtLu6KKExh8U-_v7lQ7bu3d5HP76vOd_ZHg93476qQOxyb51iTNEHCby2VV6gE9Y7LJmP6gsrsbYmS-okN6Echc0tqlSg5EI4b8gqmVlMhH_tNbju1bikDDJ5JM-WdIjMPBdLElS-5YzjxN9Ap1_Omb1QHeAil_bfzMzzHnMweTt3_rOfdRdu9741G8wnwz1Yw-Y-fNo-HMemByFW7DtlIH4ZDTpmmoqFfRJGKZYdmzTM0RxoGZFbkwkIIlU7O2YtduRo-9YHML6KLjyE9Wba4CNgVWVTZbmtsUgywwvjfX1pCpUkxis2gxG8WYyxdj3DOhX6-Kbn3NBcEx50wEMEL5eyJ3NekQulPhBUlhLEBR5uTNtj3asWnaKrVYWmKA1mNkVlEicFR17nJk9sGsHmAiS6V1CdPkNIBC-WzV610H6RaXA68zKZjz0LrhIewcYcl8svESL3zmqSRSBXELvyqastzeRroC-XqijL0j_5NmD7ku7r4WDIw9Xjy_vwHG7ujg8P9MHeaP8J3OKUdxTyBDdh_bSd4VO44X6eTrr2WZixDPQVg_4v6HV71g |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELagIMSFHwEl0IIRXECKmthOHB-3265AwGpBe-jNsp1xWQmyVbbLmUfgGXkSPE6aZdUKCXGL4rHknxnPN_b4MyGvvC1KBapKIbjXVHhwaVV6lUrLlAShgp7Y-NiEnE6rkxM163Nz8C5Mxw8xbLihZcT1Gg0czmp_sGENdcYxJEfg1XVyQxQyR6VmYrbZYkFy8chDyUK4lfIAzgeCUnawqb7lkiJz_1Vw83LW5J9oNrqjyd3_7Mg9cqfHoXTUKc59cg2aB-TT8cf5rx8_TT9lUNNvmK_3eTpaUdPUNJ4qUExIXNFFQx1qTEuRChoXzChSt-tTGkJ4hKWh9CGZT47n47dp_-ZC6orgu1PIIYRQzNu6KMFxG-CcUJyXVoK3RmQ-K0x8rMMWFlTOQTLOXXDztRQWMv6I7DTLBh4TWtc2V5ZZD2UmDCtNQMbShGA8M2EZMJCQ1xejrl3PR47PYnzVHZMy0zguOo5LQl4OsmcdC8eVUoc4eYMEMmfHH8v2VPeGqHNwXtVgysqAsDkokznJGTBfmCKzeUL2LqZe9-a80nhpL0AvzlVCXgzFwRDxdMU0sFwHGREitZKpjCVkt9OUoSWcFwHaZSIhckuHtpq6XdIsvkSyb6nKqqpCzTdRh_7SfT0ejVn8evIvws_JrdnRRH94N33_lNxmmLITU-z2yM55u4Z9ctN9P1-s2mfRuH4DVq8l3w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EMT%E2%80%90associated+microRNAs+and+their+roles+in+cancer+stemness+and+drug+resistance&rft.jtitle=Cancer+communications+%28London%2C+England%29&rft.au=Pan%2C+Guangtao&rft.au=Liu%2C+Yuhan&rft.au=Shang%2C+Luorui&rft.au=Zhou%2C+Fangyuan&rft.date=2021-03-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2523-3548&rft.volume=41&rft.issue=3&rft.spage=199&rft.epage=217&rft_id=info:doi/10.1002%2Fcac2.12138&rft_id=info%3Apmid%2F33506604&rft.externalDocID=PMC7968884 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2523-3548&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2523-3548&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2523-3548&client=summon |